EP3672689A4 - Verfahren zur behandlung eines neuroendokrinen tumors - Google Patents

Verfahren zur behandlung eines neuroendokrinen tumors Download PDF

Info

Publication number
EP3672689A4
EP3672689A4 EP18849111.2A EP18849111A EP3672689A4 EP 3672689 A4 EP3672689 A4 EP 3672689A4 EP 18849111 A EP18849111 A EP 18849111A EP 3672689 A4 EP3672689 A4 EP 3672689A4
Authority
EP
European Patent Office
Prior art keywords
treating
neuroendocrine tumor
neuroendocrine
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18849111.2A
Other languages
English (en)
French (fr)
Other versions
EP3672689A1 (de
Inventor
Darren Sigal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Clinic Medical Group Inc
Scripps Health
Original Assignee
Scripps Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Health filed Critical Scripps Health
Publication of EP3672689A1 publication Critical patent/EP3672689A1/de
Publication of EP3672689A4 publication Critical patent/EP3672689A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
EP18849111.2A 2017-08-22 2018-08-21 Verfahren zur behandlung eines neuroendokrinen tumors Withdrawn EP3672689A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/683,630 US10180422B1 (en) 2017-08-22 2017-08-22 Methods of treating a neuroendocrine tumor
PCT/US2018/047330 WO2019040497A1 (en) 2017-08-22 2018-08-21 METHOD OF TREATING A NEUROENDOCRINE TUMOR

Publications (2)

Publication Number Publication Date
EP3672689A1 EP3672689A1 (de) 2020-07-01
EP3672689A4 true EP3672689A4 (de) 2021-04-28

Family

ID=64953627

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18849111.2A Withdrawn EP3672689A4 (de) 2017-08-22 2018-08-21 Verfahren zur behandlung eines neuroendokrinen tumors

Country Status (5)

Country Link
US (2) US10180422B1 (de)
EP (1) EP3672689A4 (de)
JP (1) JP2020531467A (de)
CN (1) CN111565799A (de)
WO (1) WO2019040497A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS66346B1 (sr) 2018-10-22 2025-01-31 Alumis Inc Inhibitori tyk2 i njihova upotreba
CN110331189B (zh) * 2019-06-13 2020-10-27 南京世和基因生物技术股份有限公司 一种ntrk融合基因的检测方法、试剂盒以及探针库
CN110527722A (zh) * 2019-09-11 2019-12-03 上海交通大学 一种利用rs2644592和rs11264580检测氯吡格雷药效试剂盒
CN111235242B (zh) * 2020-04-28 2020-08-14 至本医疗科技(上海)有限公司 检测ntrk基因家族融合基因的探针库、试剂、试剂盒及应用
IL301385A (en) 2020-09-16 2023-05-01 Alumis Inc TYK2 inhibitors and their use
CN116745432A (zh) * 2020-11-03 2023-09-12 行动基因(智财)有限公司 用于检测基因变异的靶向定序方法及套组
EP4719366A1 (de) * 2023-05-26 2026-04-08 Bertram Wiedenmann Sortilin-hemmer zur behandlung von patienten mit funktionellen neuroendokrinen tumoren

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150073036A1 (en) * 2012-11-05 2015-03-12 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
US20160280690A1 (en) * 2012-11-13 2016-09-29 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2017106492A1 (en) * 2015-12-18 2017-06-22 Ignyta, Inc. Combinations for the treatment of cancer
EP3184519A1 (de) * 2014-08-18 2017-06-28 ONO Pharmaceutical Co., Ltd. Säureadditionssalz einer trk-hemmenden verbindung

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210607B1 (de) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamid zur Behandlung von Krebs
JP4242911B2 (ja) 2004-08-26 2009-03-25 ファイザー・インク プロテインキナーゼ阻害薬としてのエナンチオピュアなアミノヘテロアリール化合物
EA018503B1 (ru) 2007-07-20 2013-08-30 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Замещенные производные индазола, активные как ингибиторы киназы
EP2183254B1 (de) 2007-08-29 2017-06-21 MethylGene Inc. Inhibitoren der proteintyrosinkinaseaktivität
TWI365185B (en) 2008-07-24 2012-06-01 Lilly Co Eli Amidophenoxyindazoles useful as inhibitors of c-met
CN102264736B (zh) 2008-10-22 2013-08-14 阵列生物制药公司 作为TRK激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物
BR112012027743A2 (pt) 2010-04-29 2017-03-14 Deciphera Pharmaceuticals Llc ciclopropil dicarboxamidas e análogos exibindo atividades anticâncer e antiproliferativas
WO2012139134A2 (en) 2011-04-07 2012-10-11 Coferon, Inc. Methods of modulating oncogenic fusion proteins
TWI585088B (zh) 2012-06-04 2017-06-01 第一三共股份有限公司 作爲激酶抑制劑之咪唑并[1,2-b]嗒衍生物
US20160283883A1 (en) * 2013-11-15 2016-09-29 Hewlett Packard Enterprise Development Lp Selecting a task or a solution
US10231965B2 (en) 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells
CA2971874A1 (en) 2014-10-14 2016-04-21 Deciphera Pharmaceuticals, Llc Inhibition of trk kinase mediated tumor growth and disease progression
TWI746426B (zh) 2014-11-16 2021-11-21 美商亞雷生物製藥股份有限公司 (S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型
EP3247692B1 (de) * 2015-01-23 2022-09-07 GVK Biosciences Private Limited Inhibitoren der trka-kinase
EP3265562A4 (de) * 2015-03-05 2018-12-19 TrovaGene, Inc. Frühbeurteilung des wirkungsmechanismus und der wirksamkeit von antikrebstherapien mit molekularen markern in körperflüssigkeiten
HK1253093A1 (zh) 2015-06-01 2019-06-06 Loxo Oncology Inc. 诊断和治疗癌症的方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150073036A1 (en) * 2012-11-05 2015-03-12 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
US20160280690A1 (en) * 2012-11-13 2016-09-29 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
EP3184519A1 (de) * 2014-08-18 2017-06-28 ONO Pharmaceutical Co., Ltd. Säureadditionssalz einer trk-hemmenden verbindung
WO2017106492A1 (en) * 2015-12-18 2017-06-22 Ignyta, Inc. Combinations for the treatment of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2019040497A1 *

Also Published As

Publication number Publication date
US20190120823A1 (en) 2019-04-25
JP2020531467A (ja) 2020-11-05
CN111565799A (zh) 2020-08-21
US10180422B1 (en) 2019-01-15
WO2019040497A1 (en) 2019-02-28
EP3672689A1 (de) 2020-07-01

Similar Documents

Publication Publication Date Title
EP3402486A4 (de) Verfahren zur behandlung von c3-glomerulopathie
EP2992908A4 (de) Verfahren zur oberflächenbehandlung eines implantats
MA50169A (fr) Procédé de production d'un électrocatalyseur
FR3050672B1 (fr) Automate pour le traitement d'une surface
EP3427892A4 (de) Maschine und verfahren zur bearbeitung von dichtflächen
EP3386655C0 (de) Verfahren zur abfallverarbeitung
EP3398957A4 (de) Verfahren zur synthese von etelcalcetid
EP3766984A4 (de) Bestimmungsverfahren
EP3305732A4 (de) Abwasserbearbeitungsverfahren
EP3966554A4 (de) Verfahren zur identifizierung einer struktur
EP3392229A4 (de) Verfahren zur herstellung von hydrofluorolefin
EP3578536A4 (de) Verfahren zur herstellung von fluorhalogeniertem kohlenwasserstoff
MA40354A (fr) Procédé permettant de prédire le résultat d'un traitement avec de l'aflibercept d'un patient suspecté de souffrir d'un cancer
EP3684342A4 (de) Behandlungsverfahren
EP3966555A4 (de) Verfahren zur identifizierung einer struktur
EP3508684A4 (de) Verfahren zur behandlung des bohrlochnahen bereichs einer formation
MA50647A (fr) Procédé de régulation d'un puits
EP3630738A4 (de) Verfahren zur herstellung von ozanimod
MA42423A (fr) Procédé de préparation d'un revêtement
EP3441500A4 (de) Verfahren zur oberflächenbehandlung einer form
EP3383407A4 (de) Cytarabinkonjugate zur krebstherapie
EP3764172A4 (de) Servosteuerungsverfahren
EP3517632A4 (de) Verfahren zum betrieb eines hochofens
EP3638630A4 (de) Verfahren zur behandlung von schlamm
EP3449921A4 (de) Verfahren zur hemmung des tumorwachstums

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200306

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61P0035000000

Ipc: A61K0031496000

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40033783

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20210326

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/496 20060101AFI20210322BHEP

Ipc: G01N 33/574 20060101ALI20210322BHEP

Ipc: A61P 35/00 20060101ALI20210322BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SCRIPPS CLINIC MEDICAL GROUP, INC.

Owner name: SCRIPPS HEALTH

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230614

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20230811